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Abstract
Endoglin (ENG) is a causative gene of type 1 hereditary hemorrhagic telangiectasia (HHT1). HHT1 patients have a higher
prevalence of brain arteriovenous malformation (AVM) than the general population and patients with other HHT subtypes.
The pathogenesis of brain AVM in HHT1 patients is currently unknown and no specific medical therapy is available to treat
patients. Proper animal models are crucial for identifying the underlying mechanisms for brain AVM development and for
testing new therapies. However, creating HHT1 brain AVM models has been quite challenging because of difficulties related
to deleting Eng-floxed sequence in Eng2fl/2fl mice. To create an HHT1 brain AVM mouse model, we used several Cre
transgenic mouse lines to delete Eng in different cell-types in Eng2fl/2fl mice: R26CreER (all cell types after tamoxifen
treatment), SM22a-Cre (smooth muscle and endothelial cell) and LysM-Cre (lysozyme M-positive macrophage). An adeno-
associated viral vector expressing vascular endothelial growth factor (AAV-VEGF) was injected into the brain to induce focal
angiogenesis. We found that SM22a-Cre-mediated Eng deletion in the embryo caused AVMs in the postnatal brain, spinal
cord, and intestines. Induction of Eng deletion in adult mice using R26CreER plus local VEGF stimulation induced the brain
AVM phenotype. In both models, Eng-null endothelial cells were detected in the brain AVM lesions, and formed mosaicism
with wildtype endothelial cells. However, LysM-Cre-mediated Eng deletion in the embryo did not cause AVM in the postnatal
brain even after VEGF stimulation. In this study, we report two novel HHT1 brain AVM models that mimic many phenotypes
of human brain AVM and can thus be used for studying brain AVM pathogenesis and testing new therapies. Further, our
data indicate that macrophage Eng deletion is insufficient and that endothelial Eng homozygous deletion is required for
HHT1 brain AVM development.
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Introduction
Hereditary hemorrhagic telangiectasia (HHT), also known as
Osler-Weber-Rendu (OWR) syndrome, is the first identified
human disease caused by defects in a transforming growth
factor-ß (TGF-ß) superfamily receptor [1]. It is an autosomal
dominant genetic disorder of the blood vessels that manifests
epistaxis, mucocutaneous telangiectases, and arteriovenous mal-
formations (AVMs) in multiple organs including the brain, lung,
liver, gastrointestinal tract, and spinal cord [2]. Most of HHT
cases are categorized into either HHT type 1 (HHT1) caused by
mutations in endoglin (ENG), a TGF-ß type III auxiliary receptor
mapped on chromosome 9 [1], or HHT type 2 (HHT2) caused by
mutations in activin receptor-like kinase 1 (ACVRL1; ALK1), a
TGF-ß type I serine-threonine kinase receptor located in
chromosome 12 [3]. The prevalence of brain AVM in HHT1
patients is 1000-fold higher, and in HHT2, 100-fold higher, than
the prevalence in the general population (10/100,000) [4].
Brain AVM is a tangle of abnormal vessels called nidus, where
blood directly shunts from arteries into veins without passing the
capillary bed. These abnormal vessels tend to rupture, causing
spontaneous and recurrent hemorrhages in the brain, especially in
children and young adults [5]. The life-threatening intracranial
hemorrhage (ICH) risk rate in HHT patients ranges from 1.4% to
2% per year [6]. Currently available therapies, including
microsurgery, embolization and/or radiosurgery, are invasive
and associated with considerable side effects [7,8]. No specific
medical therapy is available for brain AVM patients.
The pathogenesis of HHT brain AVMs remains largely
unknown. A reliable animal model is crucial for studying disease
mechanisms and testing new therapies. We and others have
reported HHT2 developmental [9,10] and adult onset brain AVM
phenotypes [11] in Alk1-conditional knockout mice. No compel-
ling HHT1 brain AVM model has been reported.
We have previously shown that microscopic (capillary level)
cerebrovascular dysplasia can be induced by focal VEGF
stimulation in adult Eng-haploinsufficient (Eng+/2) mice [12].
Arteriovenous (A–V) shunting has not been identified in this
model. To create an adult onset HHT1 brain AVM model that
closely resembles human disease, we attempted using the same
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strategy that we previously used to develop an HHT2 model:
stereotactic injection of a cre-expressing adenoviral vector (Ad-
Cre) [11] and an adeno-associated viral vector expressing vascular
endothelial growth factor (AAV-VEGF). However, Ad-Cre-
mediated Eng deletion in the brain of Eng2fl/2fl mice was very
limited, in only about 1% of cells [13]. Only a few macroscopic
level dysplasia vessels developed. The objective of this study is to
establish HHT1 brain AVM mouse models that closely mimic the
human brain AVM phenotype. The secondary objective is to
explore Eng deletion in which cell-type is required for brain AVM
development.
We used several cre transgenic lines in this study to achieve
effective Eng deletion in Eng2fl/2fl mice. Striking brain AVM
phenotypes have been developed in Eng2fl/2fl;SM22a-Cre mice
spontaneously and Eng2fl/2fl;R26CreER mice after tamoxifen (TM)
treatment and focal VEGF stimulation. The AVM phenotypes in
these models mimic many characteristics of human brain AVM,
such as arteriovenous shunting, macrophage infiltration, and
microhemorrhage. Although effective Eng deletion in macrophages
was achieved, brain AVMs did not develop in Eng2fl/2fl;LysMCre
mice after VEGF stimulation, indicating that deletion of Eng in
macrophages is not sufficient to cause AVM formation. However,
homozygous Eng deletion in endothelial cells might be required for
brain AVM development, because Eng-null endothelial cells
were detected in AVM vessels in both Eng2fl/2fl;SM22aCre and
Eng2fl/2fl;R26CreER mice.
Materials and Methods
Ethics statement
The protocol and experimental procedures for using laboratory
animals were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of California, San
Francisco (UCSF). Animal husbandry was provided by the staff
of the IACUC of UCSF, under the guidance of supervisors who
are certified Animal Technologists, and by the staff of the Animal
Core Facility. Veterinary care was provided by IACUC faculty
members and veterinary residents located on the San Francisco
General Hospital campus. All mice were housed in a pathogen-
free area in 4216316 cm2 cages with 12 hours light/dark cycle.
Animals
To establish various Eng-conditional knockout mouse lines,
Eng2fl/2fl (exons 5 and 6 flanked by loxP sites) [14] mice were
crossbred with R26CreER, SM22a-Cre, and LysM-Cre [15] mice
(Jackson Laboratory, Bar Harbor, Maine).
Viral vector stereotactic injection and TM intraperitoneal
administration
AAV-VEGF or AAV-LacZ (vector control) [16] was injected
into the brain of 8 to10-week-old Eng2fl/2fl;R26CreER and
Eng2fl/2fl;LysM-Cre mice (6 mice per group), as previously
described [17]. Briefly, mice were anesthetized with isoflurane
inhalation and positioned in a stereotactic frame (David Kopf
Instruments). A hole was made in the pericranium, 1 mm
posterior to the coronal suture and 2 mm lateral to the sagittal
suture. AAV-VEGF viral suspension (26109 genome copies) was
stereotactically injected into the right basal ganglia at 3 mm in
depth from the cortex. TM dissolved in corn oil (2.5 mg/25 g of
body weight; Sigma-Aldrich) was injected intraperitoneally [9] to
Eng2fl/2fl;R26CreER mice for 3 consecutive days starting from the
day of viral vector injection (Figure S1A).
Systemic latex vascular casting
Systemic latex dye perfusion, described previously [9,11], was
performed by injecting blue latex dye (Connecticut Valley
Biological Supply) into the left ventricle of the heart. Brain, lung,
kidney, liver, intestine and ear were collected and fixed in 4%
paraformaldehyde overnight and imaged under a light micro-
scope. Organs were then sequentially dehydrated in a methanol
series, cleared in organic solvent (benzyl benzoate/benzyl alcohol,
1:1; Sigma-Aldrich), and imaged again under a light microscope.
Dysplasia index quantification
Two 20 mm-thick coronal brain sections per animal, 0.5 mm
rostral and 0.5 mm caudal to the virus injection site, were stained
with lectin (1:200; Vector Laboratories). Three areas (to the right
and left of and below the injection site) within the angiogenic
region of each section were imaged under the 20X microscopic
objective lens for quantification. Dysplasia index (number of
vessels larger than 15 mm in diameter per 100 blood vessels) was
calculated by three blinded investigators using NIH Image 1.63
software as previously described [11–13,17].
Immunohistochemistry
Mice were anesthetized with isoflurane inhalation and perfused
with heparin/PBS to remove blood. Brain samples were harvested
and frozen in dry ice, then sectioned into 20 mm sections. The
location of AVM lesions was first identified through staining 1 of
every 10 sections with lectin (1:200; Vector Laboratories). Sections
containing dysplastic vessels were then co-stained with primary
antibodies against CD31 (1:50; Abcam) and CD68 (1:50; AbD
Serotec). Each protein was subsequently visualized using fluores-
cently labeled secondary antibodies: Alexa Fluor 488 goat anti-
rabbit IgG (1:500; Invitrogen) for CD31, and Alexa Fluor 594 goat
anti-rat IgG (1:500; Invitrogen) for CD68. ENG expression was
identified by an antibody against ENG/CD105 (1:50; BD
Pharmingen) and visualized by a biotin-conjugated secondary
antibody (anti-rat IgG, 1:500; Vector Laboratories), using the
standard ABC method (Vector immunodetection kit; Vector
Laboratories). Prussian blue staining was performed according to
the protocol provided by the company (Iron Stain Kit; Sigma-
Aldrich).
Monocyte/macrophage isolation and culture
Monocytes/macrophages were isolated and cultured as previ-
ously described [17]. Briefly, bone marrow was collected from
tibias and femurs of 8-week-old Eng2fl/2fl and Eng2fl/2fl;LysM-Cre
mice and cultured in a macrophage-enriched medium containing
mouse macrophage-colony stimulating factor (M-CSF, 7.5 ng/ml;
Akron Biotech) and 10% fetal bovine serum (FBS) for 7 days.
Real-time quantitative genomic DNA PCR analysis
DNA was isolated from the brain of 3 control Eng2fl/2fl and 3
TM-treated Eng2lf/2fl;R26-CreER mice, and macrophages were
isolated from 3 Eng2fl/2fl and 3 Eng2fl/2fl;LysM-Cre mice. Recom-
bination of the Eng 2fl (floxed) allele was quantified using
Mx3000P QPCR System (Agilent Technologies). The gene
deletion efficiency was calculated as the amount of Eng 2fl in
experimental samples/Eng2fl levels in controls times 100. The
primers used for real-time qPCR are listed in Table S1.
Statistical analysis
Data are represented as mean 6 SD. Student’s t-test was used
to determine a statistical significance between groups. A p value
of,0.05 was considered statistically significant. The survival curve
HHT1 Brain AVM Mouse Models
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of Eng2fl/2fl;SM22a-Cre mice was made and the difference
between male and female mice was analyzed using Prism 6
software.
Results
Developmental onset of brain AVM in Eng2fl/2fl;SM22a-Cre
mice
The SM22a-Cre transgenic mouse induced target gene deletion
in vascular smooth muscle cells during the embryonic develop-
mental stage. In addition to vascular smooth muscle cells, SM22a-
Cre transgene has been shown to mediate gene deletion in
endothelial cells and some other cell-types [10]. To test if SM22a-
Cre-mediated Eng deletion in the embryo leads to postnatal brain
AVM, we crossbred Eng2fl/2fl mice with SM22a-Cre mice. Three
different mouse groups were obtained: Eng2fl/2fl, Eng+/2fl;SM22a-
Cre, and Eng2fl/2fl;SM22a-Cre. The AVM phenotype (greatly
enlarged and tortuous vessels) was detected in the brain of 90% (18
out of 20) of 5-week-old Eng2fl/2fl;SM22a-Cre mice that had Eng
homozygous deletion in Cre-expressing cells (Figure 1C and 1F).
More than 80% of the mice had one lesion, while the remaining
20% had 2–3 lesions. No AVM phenotype was observed in the
brain of Eng2fl/2fl littermates that did not have Cre transgene
(wildtype) (Figure 1A and 1D) and Eng+/2fl;SM22a-Cre mice that
had one Eng allele deletion (heterozygous, Figure 1B and 1E).
AVMs were also found in the spinal cord (Figure S2C) and
intestine (Figure S2F) of Eng2fl/2fl;SM22a-Cre mice, but not in
Eng2fl/2fl and Eng+/2fl;SM22a-Cre mice (Figure S2A, S2B, S2D,
and S2E). The brain lesions varied in size, location (Figure S3A
and S3B), and number. There was latex dye found in the veins
(indicative of A–V shunting), and hemorrhage in some brain and
spinal cord lesions (Figure S3C and S3D). More than 50% of the
Eng2fl/2fl;SM22a-Cre mice died before 6 weeks of age (Figure 1G).
The survival rates were similar in males and females (P = 0.47).
Adult onset brain AVM in Eng2fl/2fl;R26CreER mice after
TM treatment and focal angiogenic stimulation
To induce the adult onset HHT1 brain AVM phenotype, we
utilized the R26CreER transgenic mouse in which Cre expression
is activated by TM treatment [9] to conditionally delete the Eng
gene. Eng deletion in adult Eng2fl/2fl;R26CreER mice was induced
by intraperitoneal injection of TM for 3 consecutive days (Figure
S1A). About 60% of Eng-floxed allele was deleted in the brain
(Figure S1B). Eng deletion alone did not affect the established
vasculature in the adult brain (Figure 2A). However, the AVM
phenotype developed in AAV-VEGF-induced brain angiogenic
foci 8 weeks after induction of Eng deletion and angiogenesis
(Figure 2B). Notably, the lesions mimicked the human brain AVM
nidus (Figure 2C) and consisted of markedly enlarged vessels
(Figure 2D). More enlarged vessels were detected in AAV-VEGF-
injected sites (angiogenic foci) than in AAV-LacZ-injected (control
vector) sites in the brain of TM-treated Eng2fl/2fl;R26CreER mice
(dysplasia index: 2.960.5 versus 0.0560.05, p,0.05, Figure 2E).
Since the brain AVMs in Eng2fl/2fl;R26CreER were induced by
VEGF, the lesions were thus always located at the AAV-VEGF
injection sites. Further, the AVM phenotype was also detected
around the ear-tag wound of all TM treated Eng2fl/2fl;R26CreER
mice (Figure S4A). No AVM phenotype was found in the
contralateral uninjured ear (data not shown) and the intestine
(Figure S4B). Taken together, global conditional Eng deletion in
adult mice resulted in de novo AVMs in the brain angiogenic foci
and around the skin wound.
No AVM found in Eng2fl/2fl;LysMCre mice
We have previously shown that bone marrow-derived macro-
phages home to the brain angiogenic foci [18]. Eng+/2 mice and
WT mice transplanted with Eng+/2 bone marrow developed a
similar degree of dysplasia after VEGF stimulation [17]. These
data suggest that bone marrow-derived macrophages may play a
role in brain AVM development. To test if Eng deletion in
macrophages is sufficient to induce brain AVMs, we utilized the
LysM-Cre mouse [15] that specifically mediates target gene
recombination in lysozyme M-positive macrophages. Eng2fl/2fl;
LysM-Cre mice are born with the expected Mendelian ratio and
develop normally into the adult stage. Injection of AAV-VEGF
into the basal ganglia of 8 to 10-week-old Eng2fl/2fl;LysM-Cre mice
did not induce AVM phenotype in the brain (Figure 3). Similarly,
no AVM phenotype was observed around the ear wound (Figure
S4C) and intestine (Figure S4D). Real-time genomic DNA qPCR
analysis confirmed that more than 90% Eng was deleted in
macrophages of Eng2fl/2fl;LysM-Cre mice (Figure S5), indicating
that the lack of AVM phenotype was not due to inefficient gene
deletion. Thus, these data suggest that Eng deletion in lysozyme M-
positive macrophages alone was not sufficient to initiate AVM
formation.
Eng-null endothelial cells detected in brain AVM vessels
Dilated and dysmorphic (dysplasia) vessels were found in lectin-
stained brain sections of 5-week-old Eng2fl/2fl;SM22a-Cre mice
(Figure 4A) and around the brain angiogenic region of TM-treated
adult Eng2fl/2fl;R26CreER mice (Figure 4B), but not in the brain
angiogenic region of adult Eng2fl/2fl;LysM-Cre mice (Figure 4C).
Endothelial ENG expression was greatly reduced in the lesions of
brain sections from Eng2fl/2fl;SM22a-Cre and Eng2fl/2fl;R26CreER
mice (Figure 4D and 4E). Endothelial ENG expression in the
angiogenic foci of Eng2fl/2fl;LysM-Cre mice did not change
(Figure 4F and 4I). Notably, ENG-null endothelial cells were
found in large dysplastic vessels in cerebral lesions in both Eng2fl/2fl;
SM22a-Cre (Figure 4G) and Eng2fl/2fl;R26CreER (Fig. 5H) mice.
Further, similar to the phenotype of the Alk1-deficient model
(HHT2 model) [19] and human unruptured brain AVMs [20,21],
macrophages and microhemorrhage were observed around
dysplastic vessels in the brain of Eng2fl/2fl;SM22a-Cre and Eng2fl/2fl;
R26CreER mice (Figure 5). Thus, all of the evidence indicates that
homozygous deletion of Eng in endothelial cells is necessary for the
development of macroscopic AVM-like vessels with arteriovenous
(A–V) shunts in the mouse brain.
Discussion
In this study, we established two novel HHT1 brain AVM
mouse models: one, developmental onset, and the other, adult
onset. These models are better suited for mechanistic studies and
new drug tests than the existing HHT brain AVM models we and
others have developed [9–12]. We have also shown that
endothelial homozygous Eng deletion is required for the develop-
ment of the HHT1 brain AVM phenotype, whereas deletion of
Eng in macrophages is insufficient.
As a model for investigating AVM pathogenesis and testing
novel therapies, our HHT1 developmental model created in
Eng2fl/2fl;SM22a-Cre mice has some advantages compared to the
two HHT2 developmental brain AVM models developed in
Alk12fl/2fl;L1Cre mice [9] and Alk12fl/2fl;SM22a-Cre mice [10].
The Alk12fl/2fl;L1Cre mice died at postnatal day 5 due to massive
intracranial hemorrhage [9]. More than 50% of Alk12fl/2fl;SM22a-
Cre mice died before 2 weeks of age [10]. Such a short lifespan
limits their use in testing new therapies. In contrast, we did not
HHT1 Brain AVM Mouse Models
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observe any lethality in our Eng2fl/2fl;SM22a-Cre model until
postnatal week 3. About 30% of the mice died between 3 and 6
weeks due to cerebral and/or gastrointestinal hemorrhage. The
penetrance of the brain AVM phenotype was about 90% at 5
weeks of age. Further, there is no other manipulation, such as
angiogenic stimulation, needed to initiate brain AVM develop-
ment in addition to gene deletion. Thus, brain AVM initiation and
progression in Eng2fl/2fl;SM22a-Cre mice more closely resemble
spontaneously developed human brain AVM, making this model
more suitable for studying brain AVM pathogenesis and testing
new therapies. Since the lesion size, location, and number in this
model are highly variable, identifying the location of the AVM
lesion and quantifying the dysplasia index by tissue section would
be time consuming and challenging. However, the AVM lesions
were only detected in Eng2fl/2fl;SM22a-Cre mice, and not in
Eng2fl/2fl or Eng+/2fl;SM22a-Cre mice (Figure 1). We recorded the
presence of large AVMs in a whole-mount brain preparation
following latex casting in 90% of Eng2fl/2fl;SM22a-Cre mice. This
method detected lesions with A–V shunts (latex dye presented in
the veins). More than 80% of the mice had one lesion, and the
remaining 20%, 2–3 lesions. Thus, comparing the number of mice
with lesions in the treated and control groups could be used to
evaluate the therapeutic efficacy of new test drugs. In addition,
since Eng2fl/2fl;SM22a-Cre mice died at various times (Figure 1G),
analysis of the mortality rate could be another means of evaluating
a test drug’s effectiveness. More detailed quantification would be
extremely time consuming due to the non-specific location of the
lesions, which is a limitation of the Eng2fl/2fl;SM22a-Cre model.
The capillary level dysplasia in the brain of Eng+/2 mice
described previously does not closely resemble the human brain
AVM phenotype [12]. The major drawback of our published adult
onset brain AVM model is that a Cre-expressing adenoviral vector
was used to induce focal Alk1 deletion [11]. Because the adenoviral
vector induces potent local inflammation [22], it limits the use of
this model to the study of the role of inflammation in brain AVM
phenotype development and progression. We have overcome this
limitation in the present model by using the R26CreER transgene
to achieve conditional Eng deletion. Unlike Alk12fl/2fl;R26CreER
mice that exhibited 100% lethality 2 to 3 weeks after TM-induced
gene deletion [9], Eng2fl/2fl;R26CreER mice treated with our
selected TM dose survived more than 2 months after the induction
of Eng deletion. After intra-brain injection of AAV-VEGF,
Eng2fl/2fl;R26CreER mice developed the phenotype resembling
human brain AVM. AAV causes fewer host inflammatory and
immune responses than adenoviral vectors [22]. Therefore, this is
a better model for studying the role of inflammation in brain AVM
pathogenesis than the model induced by Ad-Cre/AAV-VEGF-
mediated focal Alk1-deletion and angiogenesis [11,19].
Figure 1. Developmental onset AVM in the postnatal brain of Eng2fl/2fl;SM22a-Cre mice. Representative images of latex dye casting show
the cerebrovasculature in the brain of 5-week-old (A) Eng2fl/2fl, (B) Eng+/2fl;SM22a-Cre, and (C) Eng2fl/2fl;SM22a-Cre mice. D–F: Enlarged images of dotted
boxes shown in A–C after the brain tissue was cleared in organic solvent. The latex-perfused vasculature inside the brain can be observed. Tangled
and dilated vessels were detected only in the brain of Eng2fl/2fl;SM22a-Cre mice. Scale bars: 1 mm in A–C and 500 mm in D–F. G: Survival curve of
Eng2fl/2fl;SM22a-Cre mice. There was no difference between male (M) and female (F) mice (P = 0.47).
doi:10.1371/journal.pone.0088511.g001
HHT1 Brain AVM Mouse Models
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We detected AVM only in the intestines of Eng2fl/2fl;SM22a-Cre
mice, but not in Eng2fl/2fl;R26CreER mice. Interestingly, adult
Alk12fl/2fl;R26CreER mice developed AVMs in their lungs and
intestines after TM treatment [9]. Additionally, Eng2fl/2fl;
R26CreER mice survived 2 months after TM treatment, whereas
all Alk12fl/2fl;R26CreER mice died within 2 to 3 weeks after TM.
We hypothesize that ineffective gene deletion in Eng2fl/2fl;
R26CreER was responsible for some of the phenotypic difference
between Eng2fl/2fl;R26CreER and Alk12fl/2fl;R26CreER. We found
in our previous study that stereotactic injection of the same dose of
Ad-Cre resulted in 16% Alk1 deletion in the brain of Alk12fl/2fl
mice and less than 1% Eng deletion in Eng2fl/2fl mice [13]. In a
future study, we will use a more powerful gene deletion system to
test this hypothesis.
The prevailing view regarding AVM manifestation in HHT is
that it is caused by haploinsufficiency of one of its causative genes.
However, ENG haploinsufficiency in endothelial cells in human
HHT lesions appears to be insufficient for AVM development
[23]. We found that Eng homozygous deletion in endothelial cells
seems to be required for brain AVM formation. Both SM22a-Cre
and R26CreER mediate recombination of loxP sites in endothelial
cells [9,10]. The fact that the brain AVM phenotype developed
only in Eng2fl/2fl;SM22a-Cre and Eng2fl/2fl;R26CreER mice, but
not in Eng+/2fl;SM22a-Cre and Eng+/2fl;R26CreER mice, suggests
that Eng homozygous deletion is necessary. These data are
consistent with our previous findings that: (1) only capillary level
(microscopic level) vascular dysplasia developed in the brain of
adult Eng+/2 and Alk1+/2 mice after intra-brain injection of AAV-
VEGF [12]; and (2) Eng homozygous deletion of ,1% endothelial
cells in the adult mouse brain was sufficient to induce the
macroscopic level of cerebrovascular dysplasia phenotype [13].
Hence, loss of function of the normal allele in the endothelium of
HHT patients might be necessary for AVM formation. Many
factors contributing to the inactivation or downregulation of the
normal allele’s function have been suggested, such as focal second-
hit somatic mutations, shedding of ENG from endothelial cells
during inflammation [24,25], and reduced endothelial ENG
signaling due to increased levels of soluble endoglin (sENG) [26].
In addition, recent studies indicate that bone marrow-derived
cells play a crucial role in tissue repair and angiogenesis
Figure 2. Adult onset brain AVM in Eng2fl/2fl;R26CreER mice after TM and VEGF treatment. A: Coronal view of latex-perfused adult Eng2fl/2fl;
R26CreER brain showing no AVM phenotype 8 weeks after TM treatment. B: AVM phenotype (white arrow) developed in the brain of Eng2fl/2fl;
R26CreER mice 8 weeks after intrabrain injection of AAV-VEGF and intraperitoneal injection of TM. C: An enlarged image of the AVM lesion. Latex-
perfused veins are clearly shown at the top and bottom of the lesion (black arrows). D: Enlarged vessels observed in a 50 mm frozen section that cuts
through the AVM lesion shown in C. E: Quantification of dysplasia index. Data: mean 6 SD. *: p,0.05. n = 6 per group. Scale bars: 1 mm in A and B
and 500 mm in C and D.
doi:10.1371/journal.pone.0088511.g002
HHT1 Brain AVM Mouse Models
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[18,27,28]. We have shown that Eng+/2 mice and WT mice
transplanted with Eng+/2 bone marrow developed a similar degree
of capillary level cerebrovascular dysplasia after VEGF stimulation
[17]. These data suggest that bone marrow cells are involved in
brain AVM pathogenesis. Macrophage is the major bone marrow-
derived cell type detected in the brain angiogenic foci [17,18,28].
To explore the role of macrophages in brain AVM development,
we used LysM-Cre transgenic mouse lines to delete Eng in
Figure 3. AVM phenotype was not detected in the brain angiogenic region of Eng2fl/2fl;LysM-Cre mice. Representative images of the
latex-casted cerebrovasculature in (A) Eng2fl/2fl and (B) Eng2fl/2fl;LysMCre adult mice 8 weeks after focal VEGF stimulation. C and D: High magnification
view of the angiogenic foci (arrows) shown in A and B. Latex was present in arteries only. No vein and enlarged and tangled vessels were detected.
Scale bars: 1 mm in A and B and 500 mm in C and D.
doi:10.1371/journal.pone.0088511.g003
Figure 4. ENG-null endothelial cells in dysplastic vessels. Representative images of lectin-stained brain sections from (A) AVM lesion of 5-
week-old Eng2fl/2fl;SM22a-Cre, (B) VEGF-induced angiogenic focus of TM-treated adult Eng2fl/2fl;R26CreER, and (C) VEGF-stimulated angiogenic focus of
adult Eng2fl/2fl;LysM-Cre mice. ENG expression in (D) Eng2fl/2fl;SM22a-Cre, (E) Eng2fl/2fl;R26CreER, and (F) Eng2fl/2fl;LysM-Cre brain. G-I: Enlarged images of
the dotted boxes shown in D-F. Arrows indicate ENG-negative endothelial cells. Scale bars: 100 mm in A–F and 10 mm in G–I.
doi:10.1371/journal.pone.0088511.g004
HHT1 Brain AVM Mouse Models
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macrophages. LysM-Cre selectively induces gene recombination in
lysozyme M-positive macrophages [15]. Mice with LysM-Cre-
driven Eng deletion during the embryonic developmental stage did
not develop the brain AVM phenotype even after VEGF
stimulation. Therefore, deletion of Eng in microphages alone is
not sufficient for brain AVM formation.
However, this finding does not rule out a potential contributory
role of macrophage endoglin during AVM pathogenesis. Eng
deficiency appears to impair monocyte adhesion and migration.
The homing ability of ENG-deficient HHT1 monocytes to the
infarcted murine heart is impaired [27,29]. Eng deficiency in
endothelial cells reduces leukocyte adhesion and transmigration
[30] and impairs the endothelial-autonomous capacity to up-
regulate SDF1 expression in response to hindlimb ischemic injury
[31]. However, macrophage load is higher in unruptured human
brain AVM lesions than in control vessels [20,21] and there is also
high monocyte/macrophage infiltration in HHT skin lesions [32].
We previously found that a systemic reduction in endoglin levels
led to a temporal difference in macrophage responses. Eng+/2
mice had fewer CD68+ cells in the peri-infarct area at 3 days but
more CD68+ cells at 60 days after permanent occlusion of a distal
middle cerebral artery [33]. It appears that in the early stages of
injury, there are fewer monocytes homing to the injury site. At
the late stage when recovery normally occurs, more macrophages
persist around abnormal vessels, potentially promoting disease
progression. In addition, extravasation of blood content from
dysplastic AVM vessels could also attract macrophage infiltration
[19,21]. Indeed, macrophages were mostly co-localized with iron
deposits around the dysplastic vessels in the two models we
present in this manuscript (Figure 5). Further study will be
needed to understand how macrophages enter the AVM lesion,
and the correlation between macrophage load and patient
outcomes.
A limitation of this study is that vascular leakage and
macrophage infiltration were not quantified in these models.
However, we did observe that these phenotypes were not as severe
as in the Alk1-deficient model we previously reported [19]. The
potential reasons include: (1) the vascular defect takes longer to
develop in Eng-deficient vessels than in Alk1-deficient vessels; and
(2) the gene deletion in our previous Alk1 model was induced by
Ad-Cre, and as a result, the inflammatory response to adenoviral
vector could have resulted in increased macrophage infiltration
and more severe vascular leakage [19]. In addition, ineffective
gene deletion in Eng2fl/2fl;R26CreER could also be a reason for a
milder phenotype. Stereotactic injection of the same dose of Ad-
Cre resulted in 16% Alk1 deletion in the brain of Alk12fl/2fl mice
and less than 1% Eng deletion in Eng2fl/2fl mice [13]. In the future,
we will observe the lesion for a longer period of time, or use a more
powerful cre system.
Although many advances have been made in the HHT field,
the underlying molecular and cellular mechanisms for AVM
formation are still unclear. Our novel mouse brain AVM models
would be valuable resources for dissecting brain AVM patho-
genesis. Studying more common familial brain AVM cases will
help us understand unknown causes of sporadic brain AVMs.
The detailed long-term natural history of these models would
also allow us to understand the progression of brain AVM,
paving the way towards improving patient care. Further,
preclinical studies using these animals will lead to the design of
a safer and more effective pharmacological therapy for HHT
brain AVM patients, which may also apply to patients with
sporadic brain AVM.
Supporting Information
Table S1 Primers used for real-time quantitative
genomic DNA PCR analysis. Matrix metalloproteinase 9
(Mmp9) was used as an internal quantitative control.
(DOCX)
Figure S1 Conditional Eng deletion in the adult mouse
using the R26CreER transgenic mouse. A: Experimental
design. TM was injected to Eng2fl/2fl;R26Cre-ER mice i.p. once
per day for 3 consecutive days. AAV-VEGF was injected into the
right basal ganglia at the time when the first dose of TM was
given. Samples were collected for phenotype analysis 8 weeks after
the TM and AAV-VEGF injection. B: Quantification of WT Eng
(2fl) allele in the genomic DNA isolated from the brain 8 weeks
after the first tamoxifen (TM) injection. n= 3 per group.
(TIF)
Figure S2 SM22a-Cre-driven Eng deletion resulted in
AVMs in the postnatal spinal cord and intestine. AVM
Figure 5. Macrophage infiltration and microhemorrhage in
brain AVM lesions of Eng2fl/2fl;SM22aCre and Eng2fl/2fl;R26CreER
mice. Dysplastic vessels were present in the brain of (A) Eng2fl/2fl;SM22a-
Cre and (B) Eng2fl/2fl;R26CreER mice. Endothelial cells were visualized by
immunostaining using an antibody specific to CD31 (an endothelial cell-
specific marker). C and D: Macrophages were detected by immuno-
staining using a CD68-specific antibody. The nuclei were stained by
DAPI. E and F: Macrophages localized around large dysplastic vessels. G
and H: Iron deposits, an indicator of hemorrhage, identified by Prussian
blue. Scale bar: 100 mm.
doi:10.1371/journal.pone.0088511.g005
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phenotypes in the (C) spinal cord and (F) intestine of Eng2fl/2fl;
SM22a-Cre mice, but not in those of control mice (A, B, D, and E).
Arteries (a) and veins (v) are shown in dark and light blue,
respectively, in the intestine of Eng2fl/2fl;SM22a-Cre mice. Scale
bars: 1 mm.
(TIF)
Figure S3 AVMs and microhemorrhages found in the
brain and spinal cord of 5-week-old Eng2fl/2fl;SM22a-
Cre mice. Examples of (A) superficially and (B) deeply located
brain AVMs. Hemorrhages (arrows) detected in some lesions of
the (C) brain and (D) spinal cord. a: Artery. v: Vein. Scale bars:
1 mm.
(TIF)
Figure S4 R26CreER-mediated conditional Eng deletion
induced de novo skin AVMs around the ear wound. A:
AVM vessels around the ear wound (*) of tamoxifen-treated
Eng2fl/2fl;R26CreER mice. B: No arteriovenous (A–V) shunts in the
intestine of Eng2fl/2fl;R26CreER mice 8 weeks after tamoxifen
treatment. No abnormal vascular phenotype observed around the
(C) ear wound (*) and in the (D) intestine of Eng2fl/2fl;LysM-Cre
mice. Scale bars: 1 mm.
(TIF)
Figure S5 LysM-Cre induced effective Eng deletion in
macrophages. Relative amount of the targeted Eng conditional
2fl allele in Eng2fl/2fl;LysM-Cre macrophages compared to that of
Eng2fl/2fl macrophages. n = 3 per group.
(TIF)
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